How to Find and Use the FDA List of Authorized Generics

Ever wondered why some generic drugs seem to be an exact mirror of the brand name, while others feel like a different product entirely? You might be looking at an Authorized Generic is a drug that is chemically identical to the brand-name version but sold without the brand label. It is essentially the brand-name drug in a plain package, often produced by the original manufacturer or a partner. Unlike traditional generics, these don't go through the usual shortcut approval process, making them a unique middle ground in the pharmacy world.

What Exactly Is the FDA Authorized Generics List?

The FDA Listing of Authorized Generics is a public record maintained by the U.S. Food and Drug Administration that tracks all authorized generic drugs currently or previously on the market . It was created because of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, which forced the government to be more transparent about these products. Because authorized generics are marketed under the original brand's New Drug Application (NDA), they don't show up in the usual places where pharmacists look for generic equivalents.

The list is updated every quarter. It doesn't just tell you the drug exists; it provides the brand name, the manufacturer, and the date the drug hit the market. For example, if you look at the October 2025 update, you'll find entries like ARTHROTEC tablets (50 mg/200 mcg) produced by Pfizer, which entered the market back in 2012. It's a vital tool for anyone trying to figure out the strategic moves brand companies make to keep their market share when patents expire.

Where to Find the Information

If you are searching for the most current data, you need to head straight to the official source. The primary access point is the FDA's dedicated webpage under the Abbreviated New Drug Application (ANDA) section. From there, you can download the listing, which is typically provided as a PDF document (recently around 1.09 MB in size).

While the PDF is the current standard, the FDA has acknowledged that a static document isn't ideal for 2026. They've announced plans to move toward a dynamic, searchable database format by the second quarter of 2026. This is a direct response to people who are tired of hitting "Ctrl+F" on a long PDF to find a single drug. Until that rolls out, the PDF remains the official gold standard for verification.

Authorized Generics vs. The Orange Book

This is where most people get tripped up. If you've spent any time in healthcare, you know the Orange Book is the official FDA publication that lists approved drug products with therapeutic equivalence evaluations . However, authorized generics are notably absent from this book. Why? Because the Orange Book tracks drugs approved via an Abbreviated New Drug Application (ANDA). Since authorized generics use the brand's own NDA, they bypass that specific listing process.

Practical Tips for Using the List

If you are a pharmacist, a researcher, or a patient looking for savings, you need to know that the FDA list has a few blind spots. The most significant issue is that the FDA doesn't always know if a drug is still being sold. The list tells you when a drug entered the market, but it rarely tells you when it left. This means you might find a drug on the list only to discover it's been discontinued for years.

To get a complete picture, try these three steps:

1. Check the Authorized Generics List to see if the brand manufacturer has released an official generic version.
2. Cross-reference with the National Drug Code (NDC) Directory. This is where you can verify the actual product identifiers and see if the drug is still registered.
3. Verify with your wholesaler. As many independent pharmacy owners have noted, the FDA list is a great academic tool, but real-time availability only comes from commercial distributors like IQVIA or direct wholesaler reports.

The Strategic Game: Why These Drugs Exist

You might wonder why a brand company would release a generic version of their own drug. It seems counterintuitive. In reality, it's a defensive move. When a patent expires, a traditional generic company often gets a 180-day window of exclusivity to be the only generic on the market, allowing them to charge higher prices. By launching an authorized generic, the brand company can compete with that first generic immediately, effectively blunting the competitor's profit margins.

This strategy is incredibly common. A 2023 study in Health Affairs found that 854 unique authorized generics launched between 2010 and 2019. Major players like Pfizer is a global pharmaceutical company that frequently utilizes authorized generics to maintain market presence , Teva, and Viatris are among the most active. In some cases, this helps consumers by providing a lower-cost version of a drug before traditional generics can flood the market, though critics argue the price drops are often too small to be meaningful.

Common Pitfalls to Avoid

Don't mistake the "Date Authorized Generic Entered Market" for a precise calendar date. The FDA admits this date usually reflects the period covered by an annual report, not the day the drug actually hit pharmacy shelves. If you see a date from 2006, the drug might have actually launched in late 2005 or early 2007.

Another common mistake is assuming that every "generic" is an "authorized generic." If you see a drug in the Orange Book with a therapeutic equivalence rating, it's a traditional generic. If it's not in the Orange Book but is listed on the Authorized Generics list, you're dealing with the brand's own version. Knowing the difference is key for insurance billing and ensuring patient consistency.